Cargando…

Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine

The purpose of this study was to identify factors associated with the increase in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S1) protein and neutralizing antibody titer following SARS-CoV-2 vaccination. This observational study was conducted among healthcare workers work...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobashi, Yurie, Shimazu, Yuzo, Kawamura, Takeshi, Nishikawa, Yoshitaka, Omata, Fumiya, Kaneko, Yudai, Kodama, Tatsuhiko, Tsubokura, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187057/
https://www.ncbi.nlm.nih.gov/pubmed/35687563
http://dx.doi.org/10.1371/journal.pone.0269917
_version_ 1784725084066283520
author Kobashi, Yurie
Shimazu, Yuzo
Kawamura, Takeshi
Nishikawa, Yoshitaka
Omata, Fumiya
Kaneko, Yudai
Kodama, Tatsuhiko
Tsubokura, Masaharu
author_facet Kobashi, Yurie
Shimazu, Yuzo
Kawamura, Takeshi
Nishikawa, Yoshitaka
Omata, Fumiya
Kaneko, Yudai
Kodama, Tatsuhiko
Tsubokura, Masaharu
author_sort Kobashi, Yurie
collection PubMed
description The purpose of this study was to identify factors associated with the increase in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S1) protein and neutralizing antibody titer following SARS-CoV-2 vaccination. This observational study was conducted among healthcare workers working for a private hospital group in Fukushima Prefecture, Japan. Two blood samples were obtained from each participant. The first sample was obtained before the first dose of BNT162b2 (Pfizer-BioNTech) vaccine, and a second sample was obtained approximately 6 weeks later. Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein, immunoglobulin M (IgM) antibody against SARS-CoV-2 N-protein, and neutralizing activity were measured using the chemiluminescent immunoassay with iFlash 3000. A total of 231 healthcare workers who agreed to participate, and were negative for anti-SARS-CoV-2 IgM antibodies at enrollment, were included in the analysis. All participants had elevated IgG antibodies and neutralizing activity above the cutoff values. A total of 174 (75.3%) and 208 (90.0%) participants experienced adverse reactions after the first and second vaccine doses, respectively. Younger age, female sex, not taking immunosuppressive or antipyretic analgesic medication regularly, a lack of local adverse reactions after the first dose, and the presence of adverse reactions (fever, muscle, and joint pain) after the second dose were associated with higher IgG antibody titers and neutralizing activity. Intake of analgesic antipyretic for adverse reactions to vaccines was not significantly associated with antibody and neutralizing activity titer production. Immune responses after vaccination may differ among individuals, and continued countermeasures to prevent SARS-CoV-2 infection are vital.
format Online
Article
Text
id pubmed-9187057
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-91870572022-06-11 Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine Kobashi, Yurie Shimazu, Yuzo Kawamura, Takeshi Nishikawa, Yoshitaka Omata, Fumiya Kaneko, Yudai Kodama, Tatsuhiko Tsubokura, Masaharu PLoS One Research Article The purpose of this study was to identify factors associated with the increase in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S1) protein and neutralizing antibody titer following SARS-CoV-2 vaccination. This observational study was conducted among healthcare workers working for a private hospital group in Fukushima Prefecture, Japan. Two blood samples were obtained from each participant. The first sample was obtained before the first dose of BNT162b2 (Pfizer-BioNTech) vaccine, and a second sample was obtained approximately 6 weeks later. Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein, immunoglobulin M (IgM) antibody against SARS-CoV-2 N-protein, and neutralizing activity were measured using the chemiluminescent immunoassay with iFlash 3000. A total of 231 healthcare workers who agreed to participate, and were negative for anti-SARS-CoV-2 IgM antibodies at enrollment, were included in the analysis. All participants had elevated IgG antibodies and neutralizing activity above the cutoff values. A total of 174 (75.3%) and 208 (90.0%) participants experienced adverse reactions after the first and second vaccine doses, respectively. Younger age, female sex, not taking immunosuppressive or antipyretic analgesic medication regularly, a lack of local adverse reactions after the first dose, and the presence of adverse reactions (fever, muscle, and joint pain) after the second dose were associated with higher IgG antibody titers and neutralizing activity. Intake of analgesic antipyretic for adverse reactions to vaccines was not significantly associated with antibody and neutralizing activity titer production. Immune responses after vaccination may differ among individuals, and continued countermeasures to prevent SARS-CoV-2 infection are vital. Public Library of Science 2022-06-10 /pmc/articles/PMC9187057/ /pubmed/35687563 http://dx.doi.org/10.1371/journal.pone.0269917 Text en © 2022 Kobashi et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kobashi, Yurie
Shimazu, Yuzo
Kawamura, Takeshi
Nishikawa, Yoshitaka
Omata, Fumiya
Kaneko, Yudai
Kodama, Tatsuhiko
Tsubokura, Masaharu
Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
title Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
title_full Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
title_fullStr Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
title_full_unstemmed Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
title_short Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine
title_sort factors associated with anti-severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the bnt162b2 vaccine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187057/
https://www.ncbi.nlm.nih.gov/pubmed/35687563
http://dx.doi.org/10.1371/journal.pone.0269917
work_keys_str_mv AT kobashiyurie factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine
AT shimazuyuzo factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine
AT kawamuratakeshi factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine
AT nishikawayoshitaka factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine
AT omatafumiya factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine
AT kanekoyudai factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine
AT kodamatatsuhiko factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine
AT tsubokuramasaharu factorsassociatedwithantisevereacuterespiratorysyndromecoronavirus2sarscov2spikeproteinantibodytiterandneutralizingactivityamonghealthcareworkersfollowingvaccinationwiththebnt162b2vaccine